HRP20171758T1 - Kombinacija dr5 agonista i anti-pd-1 antagonista i načini primjene - Google Patents
Kombinacija dr5 agonista i anti-pd-1 antagonista i načini primjene Download PDFInfo
- Publication number
- HRP20171758T1 HRP20171758T1 HRP20171758TT HRP20171758T HRP20171758T1 HR P20171758 T1 HRP20171758 T1 HR P20171758T1 HR P20171758T T HRP20171758T T HR P20171758TT HR P20171758 T HRP20171758 T HR P20171758T HR P20171758 T1 HRP20171758 T1 HR P20171758T1
- Authority
- HR
- Croatia
- Prior art keywords
- antagonist
- agonist
- cancer
- use according
- antigen
- Prior art date
Links
- 229940124060 PD-1 antagonist Drugs 0.000 title claims 40
- 239000000556 agonist Substances 0.000 title claims 38
- 238000000034 method Methods 0.000 title claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229950009964 drozitumab Drugs 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 229950002884 lexatumumab Drugs 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000004214 philadelphia chromosome Anatomy 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 229950004742 tigatuzumab Drugs 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (24)
1. PD-1 antagonista i DR5 agonista za primjenu u metodi za liječenje raka, gdje PD-1 antagonista je anti-PD-1 antitijelo ili njegov antigen-vezujući fragment, i DR5 agonista je anti-DR5 antitijelo ili njegov antigen-vezujući fragment
2. PD-1 antagonista za primjenu u metodi za liječenje raka, gdje metoda dalje sadrži administraciju DR5 agonista, gdje PD-1 antagonista je anti-PD-1 antitijelo ili njegov antigen-vezujući fragment, i DR5 agonista je anti-DR5 antitijelo ili njegov antigen-vezujući fragment
3. DR5 agonista za primjenu u metodi za liječenje raka, gdje metoda dalje sadrži administraciju PD-1 antagonista, gdje PD-1 antagonista je anti-PD-1 antitijelo ili njegov antigen-vezujući fragment, i DR5 agonista je anti-DR5 antitijelo ili njegov antigen-vezujući fragment
4. PD-1 antagonista i/ili DR5 agonista za primjenu prema bilo kojem od patentnih zahtjeva 1-3, gdje DR5 agonista je odabran od Leksatumumaba, Tigatuzumaba, Konatumumaba, Drozitumaba, HGSTR2J/KMTRS, i LBY-135.
5. PD-1 antagonista i/ili DR5 agonista za primjenu prema bilo kojem od patentnih zahtjeva 1-4, gdje PD-1 antagonista sadrži CDR1, CDR2 i CDR3 domene u varijabilnoj regiji teškog lanca koji ima sekvencu prikazanu u SEQ ID NO: 13, i CDR1, CDR2 i CDR3 domene u varijabilnoj regiji lakog lanca koji ima sekvencu prikazanu u SEQ ID NO: 15.
6. PD-1 antagonista i/ili DR5 agonista za primjenu prema bilo kojem od patentnih zahtjeva 1-5, gdje PD-1 antagonista sadrži:
(a) CDR1 varijabilne regije teškog lanca koji ima sekvencu prikazanu u SEQ ID NO: 17;
(b) CDR2 varijabilne regije teškog lanca koji ima sekvencu prikazanu u SEQ ID NO: 18;
(c) CDR3 varijabilne regije teškog lanca koja ima sekvencu prikazanu u SEQ ID NO: 19;
(d) CDR1 varijabilne regije lakog lanca koji ima sekvencu prikazanu u SEQ ID NO: 20;
(e) CDR 2 varijabilne regije lakog lanca koji ima sekvencu prikazanu u SEQ ID NO: 21; i
(f) CDR 3 varijabilne regije lakog lanca koji ima sekvencu prikazanu u SEQ ID NO: 22.
7. PD-1 antagonista i/ili DR5 agonista za primjenu prema bilo kojem od patentnih zahtjeva 1-5, gdje PD-1 antagonista sadrži varijabilne regije teških i lakih lanaca koji imaju sekvence prikazane u SEQ ID NOs: 13 i 15, redom.
8. PD-1 antagonista i/ili DR5 agonista za primjenu prema bilo kojem od patentnih zahtjeva 1-5, gdje PD-1 antagonista sadrži teške i lake lance koji imaju sekvence prikazane u SEQ ID NOs: 11 i 12, redom.
9. PD-1 antagonista i/ili DR5 agonista za primjenu prema bilo kojem od patentnih zahtjeva 1-8, gdje administracija PD-1 antagonista i DR5 agonista smanjuje veličinu tumora za najmanje 50%.
10. PD-1 antagonista i/ili DR5 agonista za primjenu prema bilo kojem od patentnih zahtjeva 1-8, gdje administracija PD-1 antagonista i DR5 agonista, smanjuje veličinu tumora za najmanje 80%.
11. PD-1 antagonista i/ili DR5 agonista za primjenu prema bilo kojem od patentnih zahtjeva 1-8, gdje administracija PD-1 antagonista i DR5 agonista dovodi do inhibicije rasta tumora od najmanje 80%.
12. PD-1 antagonista i/ili DR5 agonista za primjenu prema bilo kojem od patentnih zahtjeva 1-8, gdje liječenje proizvodi najmanje jedan terapijski efekt izabran od smanjenja veličine tumora, smanjenja broja metastatskih lezija tijekom vremena, kompletnog odgovora, djelomičnog odgovora i stabilne bolesti.
13. PD-1 antagonista i/ili DR5 agonista za primjenu prema bilo kojem od patentnih zahtjeva 1-12, gdje PD-1 antagonista i DR5 agonista su formulirani za intravensku administraciju.
14. PD-1 antagonista i/ili DR5 agonista za primjenu prema bilo kojem od patentnih zahtjeva 1-12, gdje metoda sadrži administriranje PD-1 antagonista prije administriranja DR5 agonista.
15. PD-1 antagonista i/ili DR5 agonista za primjenu prema bilo kojem od patentnih zahtjeva 1-12, gdje metoda sadrži administriranje DR5 agonista prije administriranja PD-1 antagonista.
16. PD-1 antagonista i/ili DR5 agonista za primjenu prema bilo kojem od patentnih zahtjeva 1-12, gdje metoda sadrži administriranje DR5 agonista i PD-1 antagonista istovremeno.
17. PD-1 antagonista i/ili DR5 agonista za primjenu prema bilo kojem od patentnih zahtjeva 1-16, gdje rak je rak odabran od leukemije, limfoma, blastoma, karcinoma i sarkoma.
18. PD-1 antagonista i/ili DR5 agonista za primjenu prema bilo kojem od patentnih zahtjeva 1-16, gdje je rak odabran od kronične mijeloične leukemije, akutne limfoblastična leukemije, akutne limfoblastične leukemije pozitivne na Philadelphia kromosom (Ph+ ALL), karcinoma skvamoznih stanica, sitnostaničnog raka pluća, nesitnostaničnog raka pluća, glioma, gastrointestinalnog raka, raka bubrega, raka jajnika, raka jetre, kolorektalnog raka, raka endometrija, raka bubrega, raka prostate, raka štitnjače, neuroblastoma, raka gušterače, glioblastoma multiforme, raka grlića maternice, raka trbuha, raka mokraćnog mjehura, hepatoma, raka dojke, raka debelog crijeva, raka glave i vrata, raka želuca, tumora zametnih stanica, pedijatrijskog sarkoma, sinonasalnog prirodnog ubojice, multiplog mijeloma, akutne mijelogene leukemije (AML), i kronične limfocitne leukemije (CML).
19. PD-1 antagonista i/ili DR5 agonista za primjenu prema bilo kojem od patentnih zahtjeva 1-18, gdje metoda za liječenje raka dalje sadrži administraciju dodatnog terapijskog agensa.
20. PD-1 antagonista i/ili DR5 agonista za primjenu prema patentnom zahtjevu 19, gdje dodatni terapijski agens je citotoksin ili kemoterapijski agens.
21. PD-1 antagonista i/ili DR5 agonista za primjenu prema bilo kojem od patentnih zahtjeva 1-20, gdje subjekt koga treba liječiti je čovjek.
22. Kompozicija koja sadrži PD-1 antagonistu i DR5 agonistu, gdje PD-1 antagonista je anti-PD-1 antitijelo ili njegov antigen-vezujući fragment, i DR5 agonista je anti-DR5 antitijelo ili njegov antigen-vezujući fragment.
23. Kompozicija iz patentnog zahtjeva 22 za primjenu u metodi za liječenje raka.
24. Set za liječenje raka kod subjekta, set koji sadrži:
(a) dozu PD-1 antagonista;
(b) dozu DR5 agonista; i
(c) instrukcije za primjenu PD-1 antagonista i DR5 agonista prema bilo kojem od patentnih zahtjeva 1-23,
gdje PD-1 antagonista je anti-PD-1 antitijelo ili njegov antigen-vezujući fragment, i DR5 agonista je anti-DR5 antitijelo ili njegov antigen-vezujući fragment.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783184P | 2013-03-14 | 2013-03-14 | |
| EP14717294.4A EP2970473B1 (en) | 2013-03-14 | 2014-03-12 | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use |
| PCT/US2014/024208 WO2014159562A1 (en) | 2013-03-14 | 2014-03-12 | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171758T1 true HRP20171758T1 (hr) | 2017-12-29 |
Family
ID=50483524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171758TT HRP20171758T1 (hr) | 2013-03-14 | 2017-11-14 | Kombinacija dr5 agonista i anti-pd-1 antagonista i načini primjene |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20160067337A1 (hr) |
| EP (2) | EP3305812B1 (hr) |
| CY (1) | CY1119510T1 (hr) |
| DK (1) | DK2970473T3 (hr) |
| ES (2) | ES2812208T3 (hr) |
| HR (1) | HRP20171758T1 (hr) |
| HU (1) | HUE035865T2 (hr) |
| LT (1) | LT2970473T (hr) |
| ME (1) | ME02917B (hr) |
| NO (1) | NO3080374T3 (hr) |
| PL (1) | PL2970473T3 (hr) |
| PT (1) | PT2970473T (hr) |
| RS (1) | RS56531B1 (hr) |
| SI (1) | SI2970473T1 (hr) |
| WO (1) | WO2014159562A1 (hr) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101495951B1 (ko) | 2009-03-30 | 2015-02-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 리포솜 조성물 |
| WO2013173223A1 (en) * | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| ME02917B (me) | 2013-03-14 | 2018-10-20 | Bristol Myers Squibb Co | Kombinacija dr5 agoniste i anti-pd--1 antagoniste i načini primjene |
| PE20160953A1 (es) | 2013-12-12 | 2016-09-26 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| GB201419084D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-PD-1 antibodies |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| SG11201706024YA (en) | 2015-01-26 | 2017-08-30 | Macrogenics Inc | Multivalent molecules comprising dr5-binding domains |
| CA2978311A1 (en) * | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and eribulin for treating cancer |
| JP2018521983A (ja) | 2015-07-16 | 2018-08-09 | バイオカイン セラピューティックス リミテッド | がんを治療するための組成物および方法 |
| BR112018008867A8 (pt) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e seus usos |
| EP3389714A4 (en) | 2015-12-14 | 2019-11-13 | MacroGenics, Inc. | BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY TO PD-1 AND CTLA-4 AND METHODS OF USE |
| RS64588B1 (sr) | 2015-12-22 | 2023-10-31 | Regeneron Pharma | Kombinacija anti-pd-1 antitela i bispecifičnih anti-cd20/anti-cd3 antitela za lečenje kancera |
| WO2017173360A2 (en) * | 2016-03-31 | 2017-10-05 | Stcube, Inc. | Combination treatments directed toward programmed death ligand-1 (pd-l1) positive cancers |
| WO2017188350A1 (ja) | 2016-04-28 | 2017-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TW202408578A (zh) | 2016-05-13 | 2024-03-01 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| IL263834B2 (en) | 2016-06-20 | 2024-01-01 | Kymab Ltd | Antibodies against PD-L1 |
| RU2764548C2 (ru) | 2016-08-09 | 2022-01-18 | Кимаб Лимитед | Анти-icos антитела |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| US20200150125A1 (en) | 2017-03-12 | 2020-05-14 | Yeda Research And Development Co., Ltd. | Methods of diagnosing and prognosing cancer |
| WO2018167780A1 (en) | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of prognosing and treating cancer |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| WO2019122882A1 (en) | 2017-12-19 | 2019-06-27 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| AU2019218125A1 (en) * | 2018-02-08 | 2020-08-20 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| EP3759229A4 (en) * | 2018-02-26 | 2021-12-29 | IGM Biosciences Inc. | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
| CN108840932B (zh) * | 2018-04-28 | 2022-03-29 | 中国科学院微生物研究所 | 一种pd-1特异性抗体及其抗肿瘤应用 |
| AU2019360044A1 (en) | 2018-10-17 | 2021-05-27 | Biolinerx Ltd. | Treatment of metastatic pancreatic adenocarcinoma |
| US20220096539A1 (en) * | 2019-01-18 | 2022-03-31 | University Of Georgia Research Foundation, Inc. | Salt nanoparticles and compositions and methods of use thereof |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| CN110982824B (zh) * | 2019-10-09 | 2022-04-15 | 天津大学 | 拮抗pd-1的抗体类似物bp基因及蛋白和应用 |
| WO2021260675A1 (en) | 2020-06-24 | 2021-12-30 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
| JP2023532768A (ja) | 2020-07-07 | 2023-07-31 | バイオエヌテック エスエー | Ｈｐｖ陽性癌の治療用ｒｎａ |
| EP4214239A1 (en) * | 2020-10-14 | 2023-07-26 | University of Virginia Patent Foundation | Compositions and methods for overcoming dr5-induced immune evasion by solid tumors |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
| WO2022243378A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| KR20240046323A (ko) | 2021-07-13 | 2024-04-08 | 비온테크 에스이 | 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제 |
| WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
| WO2024115725A1 (en) | 2022-12-01 | 2024-06-06 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
| WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| WO2024160721A1 (en) | 2023-01-30 | 2024-08-08 | Kymab Limited | Antibodies |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1763223A (en) | 1927-04-02 | 1930-06-10 | Owens Illinois Glass Co | Glassware-annealing leer |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| AU643109B2 (en) | 1990-12-14 | 1993-11-04 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| WO1996004388A1 (en) | 1994-07-29 | 1996-02-15 | Smithkline Beecham Plc | Novel compounds |
| US6284236B1 (en) | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
| NZ311982A (en) | 1995-06-29 | 1999-08-30 | Immunex Corp | Tnf related apoptosis inducing ligand (trail), a method for producing them and associated antibodies |
| US6046048A (en) | 1996-01-09 | 2000-04-04 | Genetech, Inc. | Apo-2 ligand |
| US6713061B1 (en) | 1996-03-12 | 2004-03-30 | Human Genome Sciences, Inc. | Death domain containing receptors |
| WO1997033904A1 (en) | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
| US7357927B2 (en) | 1996-03-12 | 2008-04-15 | Human Genome Sciences, Inc. | Death domain containing receptors |
| US6469144B1 (en) | 1996-04-01 | 2002-10-22 | Genentech, Inc. | Apo-2LI and Apo-3 polypeptides |
| EP1012274B2 (en) | 1997-01-28 | 2011-06-15 | Human Genome Sciences, Inc. | Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l) |
| US6433147B1 (en) | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
| US6072047A (en) | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
| US7528239B1 (en) | 1997-02-13 | 2009-05-05 | Immunex Corporation | Receptor that binds trail |
| US20020160446A1 (en) | 2000-11-14 | 2002-10-31 | Holtzman Douglas A. | Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses |
| US6313269B1 (en) | 1997-03-14 | 2001-11-06 | Smithkline Beecham Corporation | Tumor necrosis factor related receptor, TR6 |
| US20010010924A1 (en) | 1997-03-14 | 2001-08-02 | Keith Charles Deen | Tumor necrosis factor related receptor, tr6 polynecleotides |
| CN1624128A (zh) | 1997-03-17 | 2005-06-08 | 人类基因组科学公司 | 包含死亡结构域的受体－5 |
| US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| AU7126498A (en) | 1997-04-16 | 1998-11-11 | Millennium Pharmaceuticals, Inc. | Tumor necrosis factor receptor related proteins tango-63d and tango-63e |
| PT1860187E (pt) | 1997-05-15 | 2011-10-04 | Genentech Inc | Receptor apo-2 |
| US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| US6506569B1 (en) | 1997-05-30 | 2003-01-14 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR10 |
| US6214580B1 (en) | 1997-05-30 | 2001-04-10 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor tr10 |
| IL133122A0 (en) | 1997-06-18 | 2001-03-19 | Genentech Inc | Apo-2dcr polypeptides |
| WO1999002653A1 (en) | 1997-07-11 | 1999-01-21 | Trustees Of The University Of Pennsylvania | Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use |
| JP2001514888A (ja) | 1997-08-15 | 2001-09-18 | アイドゥン ファーマシューティカルズ， インコーポレイテッド | Ｔｒａｉｌレセプター、これをコードする核酸、およびその使用方法 |
| WO1999011791A2 (en) | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
| PT1045906E (pt) | 1998-01-15 | 2009-01-27 | Genentech Inc | Ligando apo-2 |
| WO2000066156A1 (en) | 1999-05-04 | 2000-11-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| JP2002544172A (ja) | 1999-05-06 | 2002-12-24 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 死ドメイン含有レセプター４ |
| EP1187842B1 (en) | 1999-05-28 | 2006-04-26 | Human Genome Sciences, Inc. | Fc fusion proteins of the HUMAN TUMOR NECROSIS FACTOR RECEPTOR TR10 |
| AU2002309647C1 (en) | 2001-05-25 | 2008-09-11 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| AU2002330039A1 (en) | 2001-09-17 | 2003-04-01 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
| US20030180296A1 (en) | 2001-12-20 | 2003-09-25 | Theodora Salcedo | Antibodies that immunospecifically bind to trail receptors |
| AU2003259835A1 (en) | 2002-08-15 | 2004-03-03 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| WO2007005874A2 (en) | 2005-07-01 | 2007-01-11 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| AU2008319298B2 (en) | 2007-10-31 | 2014-07-31 | Medimmune, Llc | Protein scaffolds |
| EP2379585A2 (en) | 2008-10-10 | 2011-10-26 | Anaphore, Inc. | Polypeptides that bind trail-ri and trail-r2 |
| SI2483310T1 (sl) | 2009-09-29 | 2014-12-31 | Roche Glycart Ag | Bispecifiäśna agonistiäśna protitelesa receptorja smrti |
| US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| CA2795325A1 (en) | 2010-04-13 | 2011-10-20 | Medimmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
| US20130064838A1 (en) | 2010-05-14 | 2013-03-14 | Amgen Inc. | Enhanced death receptor agonists |
| AU2014244117B2 (en) | 2013-03-13 | 2018-12-20 | Oncoceutics, Inc. | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one |
| US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| ME02917B (me) | 2013-03-14 | 2018-10-20 | Bristol Myers Squibb Co | Kombinacija dr5 agoniste i anti-pd--1 antagoniste i načini primjene |
| CA2968961A1 (en) * | 2014-11-25 | 2016-06-02 | Bristol-Myers Squibb Company | Methods and compositions for 18f-radiolabeling of biologics |
| CN110740749A (zh) * | 2017-03-14 | 2020-01-31 | 戊瑞治疗有限公司 | 在酸性pH下与VISTA结合的抗体 |
| JP7411627B2 (ja) * | 2018-07-09 | 2024-01-11 | ファイヴ プライム セラピューティクス インク | Ｉｌｔ４と結合する抗体 |
-
2014
- 2014-03-12 ME MEP-2017-263A patent/ME02917B/me unknown
- 2014-03-12 EP EP17186093.5A patent/EP3305812B1/en active Active
- 2014-03-12 HU HUE14717294A patent/HUE035865T2/en unknown
- 2014-03-12 RS RS20171159A patent/RS56531B1/sr unknown
- 2014-03-12 DK DK14717294.4T patent/DK2970473T3/da active
- 2014-03-12 SI SI201430375T patent/SI2970473T1/sl unknown
- 2014-03-12 PT PT147172944T patent/PT2970473T/pt unknown
- 2014-03-12 ES ES17186093T patent/ES2812208T3/es active Active
- 2014-03-12 LT LTEP14717294.4T patent/LT2970473T/lt unknown
- 2014-03-12 US US14/774,382 patent/US20160067337A1/en not_active Abandoned
- 2014-03-12 ES ES14717294.4T patent/ES2644022T3/es active Active
- 2014-03-12 EP EP14717294.4A patent/EP2970473B1/en active Active
- 2014-03-12 WO PCT/US2014/024208 patent/WO2014159562A1/en active Application Filing
- 2014-03-12 PL PL14717294T patent/PL2970473T3/pl unknown
- 2014-11-20 NO NO14806207A patent/NO3080374T3/no unknown
-
2017
- 2017-10-30 CY CY20171101131T patent/CY1119510T1/el unknown
- 2017-11-14 HR HRP20171758TT patent/HRP20171758T1/hr unknown
-
2018
- 2018-05-31 US US15/993,687 patent/US11103579B2/en active Active
-
2021
- 2021-07-28 US US17/387,399 patent/US20220098302A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2970473B1 (en) | 2017-08-16 |
| EP3305812A1 (en) | 2018-04-11 |
| ES2644022T3 (es) | 2017-11-27 |
| CY1119510T1 (el) | 2018-03-07 |
| SI2970473T1 (sl) | 2017-10-30 |
| ME02917B (me) | 2018-10-20 |
| RS56531B1 (sr) | 2018-02-28 |
| HUE035865T2 (en) | 2018-05-28 |
| US20220098302A1 (en) | 2022-03-31 |
| EP3305812B1 (en) | 2020-06-17 |
| ES2812208T3 (es) | 2021-03-16 |
| WO2014159562A1 (en) | 2014-10-02 |
| US11103579B2 (en) | 2021-08-31 |
| PL2970473T3 (pl) | 2018-01-31 |
| PT2970473T (pt) | 2017-10-26 |
| DK2970473T3 (da) | 2017-11-27 |
| US20160067337A1 (en) | 2016-03-10 |
| LT2970473T (lt) | 2017-10-25 |
| US20180360962A1 (en) | 2018-12-20 |
| NO3080374T3 (hr) | 2018-03-24 |
| EP2970473A1 (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171758T1 (hr) | Kombinacija dr5 agonista i anti-pd-1 antagonista i načini primjene | |
| JP2024037894A5 (hr) | ||
| JP2018534933A5 (hr) | ||
| HRP20201404T1 (hr) | Postupci liječenja raka primjenom pd-1 osno vezujućeg antagonista i inhibitora tigita | |
| JP2019519499A5 (hr) | ||
| JP6130871B2 (ja) | Ｃｄ３８を特異的に認識する抗体とビンクリスチンとを含有する抗腫瘍組合せ | |
| JP6018235B2 (ja) | Ｃｄ３８を特異的に認識する抗体とシクロホスファミドとを含有する抗腫瘍組合せ | |
| JP2017533912A5 (hr) | ||
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| RU2017133273A (ru) | Ингибиторы pd-1 / pd-l1 для лечения рака | |
| HRP20230517T1 (hr) | Kombinacija anti-pd-1 antitijela i radijacijske terapije za liječenje raka | |
| JP2018516969A5 (hr) | ||
| JP2019506403A5 (hr) | ||
| JP2017514795A5 (hr) | ||
| JP2018503365A5 (hr) | ||
| RU2009132674A (ru) | Комбинированная терапия с использованием ингибиторов ангиогенеза | |
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| RU2018135317A (ru) | Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии | |
| JP2020528750A5 (hr) | ||
| HRP20240338T1 (hr) | Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 | |
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2018508512A5 (hr) | ||
| RU2014138040A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost |